Proactive investors

Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

The Amphion management team has been working together for over twenty years.  We have been directly involved in the start-up and development of more than thirty-five companies in the medical and information technology sectors. As anyone who has done this can testify, starting and building technology intensive companies takes commitment and experience, patience and persistence and above all, a systematic approach.

The Amphion model is designed to embrace one new company per year.  It starts with a rigorous selection process.  We choose carefully because we know that once we adopt a new Partner Company, we plan to see it through to success.  We are not just investors but builders and partners with the inventors, founders, and management teams we support.   Before we commit to a new Partner Company, we immerse ourselves over many months in the technology and the markets it will address, digging into key aspects of the business proposition.  We need to be happy with the strength of the intellectual property, the financing profile and the people and we need to be sure we are working with a technology that has demonstrated “proof of concept”.  We don’t want to speculate on a technology, however exciting, that may or may not work.  We want to be sure that our role is to help the company develop and market a product that will address existing market segments and become a good business.

The pace of technical innovation in medicine and IT shows no signs of slackening.  The convergence of scientific disciplines is throwing up more opportunities for important products, many of which will change or save lives and some of which have the potential to be commercially successful if supported in the right way. The Amphion team’s skill is to select these opportunities and support them through the process of achieving their objectives.

Richard M. Mansell-Jones, Non-executive Chairman

Robert J. Bertoldi, President, Chief Financial Officer, and Executive Director

Anthony W. Henfrey, Non-executive Director

R. James Macaleer, Non-executive Director

Richard C. E. Morgan, CEO and Executive Director

Gerard M. Moufflet, Non-executive Director

Katharine B. Cushing, Strategic Investment Advisor

Joseph R. Flicek, Managing Director

Jerel Whittingham, Managing Director

No info available.

• Access Pharmaceuticals (OTCBB: ACCP)
• Alliance Pharma (AIM: APH)
• Asterand (LSE: ATD)
• Biocompatibles (LSE: BII)
• BioNeutral Group (OTCBB: BONU)
• Bionomics (ASX: BNO)
• Circadian Technologies Limited (ASX: CIR)
• CogState (ASX: CGS)
• e-Therapeutics plc (AIM: ETX)
• Eco Animal Health Group Plc (AIM: EAH)
• Epistem (AIM: EHP)
• ImmuPharma PLC (AIM: IMM)
• Lipoxen (AIM: LPX)
• Medical Australia Limited (ASX: MLA)
• Oxford Nutrascience (AIM: ONG)
• Renovo Group Plc (LSE: RNVO)
• Rexahn Pharmaceuticals (AMEX: RNN)
• Silence Therapeutics (AIM: SLN)
• Starpharma (ASX: SPL)
• Stirling Products Limited (ASX: STI)